# T&W Medical A/S

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/twmedical).

## Overview

T&W Medical A/S is a Danish investment holding company focused on equity investments in medtech and life science businesses. Through its group interests, it is exposed to products and technologies related to hearing care, epilepsy care, and other medical and health-related solutions.

## Products & services

• Equity ownership in medtech and life science companies
• Hearing aid and hearing-care products through group interests
• Implantable epilepsy monitoring and EEG solutions
• Investment in private companies and related assets

- **Hearing care solutions** (95%) — Hearing aids and associated hearing-care products sold through operating group interests.
- **Neurology and epilepsy devices** (3%) — Implantable and EEG-based devices and solutions for epilepsy and neurological care.
- **Investment holdings** (2%) — Ownership interests in medtech and life science companies and related investments.

- Equity ownership in medtech and life science companies
- Hearing aid and hearing-care products through group interests
- Implantable epilepsy monitoring and EEG solutions
- Investment in private companies and related assets

## Customers

The company serves end users and healthcare channels through its operating interests, especially people needing hearing solutions and patients with epilepsy-related care needs. Its products are also sold through audiology professionals, clinics, and independent distributors that support diagnosis, fitting, and ongoing device use.

- **Hearing-impaired consumers** (primary) — Buy hearing aids and related products to improve daily hearing and communication.
- **Audiology professionals and clinics** (primary) — Purchase, fit, and service hearing solutions for end users.
- **Independent distributors** (secondary) — Buy hearing products for resale in local markets and channel coverage.
- **Epilepsy care patients and providers** (secondary) — Use EEG and implantable devices for monitoring and managing epilepsy care.

- Hearing-impaired consumers who need fitted hearing devices
- Audiology clinics and hearing-care professionals
- Independent distributors serving local hearing markets
- Epilepsy patients and neurological care providers
- Healthcare systems that use specialized monitoring devices

## Geography

The group has a global operating footprint through its hearing-care interests, with products sold worldwide via own sales companies and independent distributors. Denmark is the company’s home base, while the underlying businesses depend on international markets, supply chains, and regulatory approvals across multiple countries.

- Denmark is the company’s home country and reporting base
- Operating interests sell hearing products globally
- Own sales companies support direct market coverage
- Independent distributors expand reach in local markets
- International supply chains and regulations shape execution

## Strategy

T&W Medical’s stated focus is to own and invest in high-technology medtech and life science companies that improve quality of life. The portfolio approach combines long-term ownership with exposure to specialized healthcare technologies and established commercial platforms.

- **Build value through medtech ownership** (long-term) — The holding company model depends on developing and supporting businesses with durable medical technology positions.
- **Support commercial scale in core health platforms** (medium-term) — Global distribution and product adoption are central to monetizing specialized healthcare technologies.

- Own and invest in high-technology medtech businesses
- Back products that address hearing loss and epilepsy
- Support businesses with global commercialization potential
- Maintain exposure to both listed and unlisted assets

## Risks

The business is exposed to operating-company risks from medtech commercialization, including competition, product development, and regulatory approval requirements. It also faces supply-chain, cyber, foreign exchange, and refinancing risks through its underlying group interests and international operations.

- **Regulatory and approval risk** [high] — Medical devices require approvals across jurisdictions, and standards can change over time.
- **Supply chain disruption** [high] — The operating businesses rely on international suppliers for components.
- **Cybersecurity and IT disruption** [high] — Ransomware or data breaches can halt operations and affect sensitive medical information.
- **Refinancing and interest rate risk** [high] — Floating-rate debt and maturity refinancing can pressure cash flow if markets tighten.

- Medtech regulation can delay launches and raise compliance costs
- Supply chain disruptions can affect product availability
- Cyberattacks can interrupt production and expose sensitive data
- Foreign exchange and interest rates can affect financing and results

## Accounting

The annual report is prepared under IFRS as adopted by the EU, with judgment required around acquisitions, intangible assets, and special items. The group also highlights amortization of identifiable assets from purchase price allocations, which can materially affect operating profit and comparability across periods.

- **Purchase price allocation amortization** — Reported operating profit
- **Special items** — Adjusted EBITDA and EBIT
- **Intangible asset impairment** — Asset carrying values and earnings

- Purchase price allocation amortization affects EBIT and comparability
- Special items can exclude non-recurring acquisition or restructuring costs
- Debt and hedging accounting affect finance costs and liquidity metrics
- Goodwill and intangible asset values require periodic impairment review

---

*Last updated: 2026-10-24T15:20:30.882242+00:00*